All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

December 28th 2024

Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.

Community Practice Training During Fellowship Often Falls Short

December 28th 2024

A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.

FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

December 27th 2024

The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.

A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology

December 27th 2024

A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s minds of medicine to improve outcomes further.

Reflections of an Inaugural Gynecologic Oncology Fellow

December 27th 2024

Nujsaubnusi Vue, MD, shares reflections on the challenges, successes, and failures that she's encountered thus far as an inaugural fellow.

A Pioneering Journey in Radiation Oncology Inspired by Multidisciplinary Collaboration

December 27th 2024

Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.

New Advances in Waldenström Macroglobulinemia

December 27th 2024

Understanding Waldenström Macroglobulinemia, and genomic profiles influencing clinical presentation and treatment strategies.

FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or Metastatic Gastric/GEJ Cancer

December 27th 2024

The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

National Fellows Forum Highlights Future Research Directions in HGSOC and HCC

December 26th 2024

Oncology fellows gathered at the OncLive National Fellows Forum to share research findings, network, and join panels on career development strategies.

Uncovering the Power of Introspection to Drive Personalized Cancer Care

December 26th 2024

A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

December 26th 2024

Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.

Pilot Program Improves Palliative Care Training for Hematology/Oncology Fellows

December 25th 2024

The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.

Novel Therapies and Combinations Augment Melanoma Treatment Arsenal

December 25th 2024

Omid Hamid, MD, discusses recent advances in the melanoma treatment landscape and highlights the 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®.

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

December 24th 2024

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Rewriting the Rules for a Better Future of Cancer Care

December 24th 2024

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Combination Regimens Make Their Mark in Frontline HCC

December 24th 2024

In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

December 23rd 2024

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

December 23rd 2024

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.